玻璃体内注射奥克纤溶酶后的板层黄斑裂孔
Lamellar macular hole after intravitreal ocriplasmin injection.
作者信息
Chod Ross Bronson, Goodrich Clifford, Saxena Sandeep, Akduman Levent
机构信息
Department of Ophthalmology, St Louis University Eye Institute, St Louis, Missouri, USA.
Department of Ophthalmology, CSM Medical University, Lucknow, Uttar Pradesh, India.
出版信息
BMJ Case Rep. 2015 Jan 9;2015:bcr2014207810. doi: 10.1136/bcr-2014-207810.
Abstract
Intravitreal ocriplasmin was recently approved by the Food and Drug Administration to achieve medical vitreolysis in the setting of vitreomacular adhesion (VMA). We report a case of a 76-year-old woman who developed a lamellar macular hole following treatment with intravitreal ocriplasmin injection for VMA. A pathophysiological mechanism to explain this previously unreported complication of ocriplasmin injection is proposed.
摘要
玻璃体内注射奥克纤溶酶最近被美国食品药品监督管理局批准用于在玻璃体黄斑粘连（VMA）情况下实现医源性玻璃体溶解。我们报告了一例76岁女性患者，她在接受玻璃体内注射奥克纤溶酶治疗VMA后出现了板层黄斑裂孔。本文提出了一种病理生理机制来解释这种先前未报道的奥克纤溶酶注射并发症。
相似文献
1
Lamellar macular hole after intravitreal ocriplasmin injection.
BMJ Case Rep. 2015 Jan 9;2015:bcr2014207810. doi: 10.1136/bcr-2014-207810.
2
Results of the 2-Year Ocriplasmin for Treatment for Symptomatic Vitreomacular Adhesion Including Macular Hole (OASIS) Randomized Trial.
Ophthalmology. 2016 Oct;123(10):2232-47. doi: 10.1016/j.ophtha.2016.06.043. Epub 2016 Aug 4.
3
Baseline Predictors of Vitreomacular Adhesion/Traction Resolution Following an Intravitreal Injection of Ocriplasmin.
Ophthalmic Surg Lasers Imaging Retina. 2016 Aug 1;47(8):716-23. doi: 10.3928/23258160-20160808-04.
4
Visual function response to ocriplasmin for the treatment of vitreomacular traction and macular hole.
Acta Ophthalmol. 2017 Dec;95(8):e740-e745. doi: 10.1111/aos.13369. Epub 2017 Jan 30.
5
Early vitreomacular separation with delayed macular hole closure after ocriplasmin treatment.
Indian J Ophthalmol. 2016 Mar;64(3):222-4. doi: 10.4103/0301-4738.181746.
6
Association between anatomical resolution and functional outcomes in the mivi-trust studies using ocriplasmin to treat symptomatic vitreomacular adhesion/vitreomacular traction, including when associated with macular hole.
Retina. 2015 Jun;35(6):1151-7. doi: 10.1097/IAE.0000000000000508.
7
Anatomical and visual outcomes following ocriplasmin treatment for symptomatic vitreomacular traction syndrome.
Br J Ophthalmol. 2014 Mar;98(3):356-60. doi: 10.1136/bjophthalmol-2013-304219. Epub 2013 Dec 19.
8
Delayed full-thickness macular hole closure without vitreomacular traction release following ocriplasmin injection.
BMJ Case Rep. 2015 Sep 10;2015:bcr2015212181. doi: 10.1136/bcr-2015-212181.
9
[Clinical evaluation of ocriplasmin as a vitreolytic agent].
Zhonghua Yan Ke Za Zhi. 2015 Feb;51(2):155-60.
10
From the analysis of pharmacologic vitreolysis to the comprehension of ocriplasmin safety.
Expert Opin Drug Saf. 2016 Sep;15(9):1267-78. doi: 10.1080/14740338.2016.1208169. Epub 2016 Jul 20.
引用本文的文献
1
[Microstructural retinal changes after pharmacological vitreolysis with ocriplasmin-an SD-OCT supported analysis].
Ophthalmologe. 2020 Mar;117(3):260-266. doi: 10.1007/s00347-019-0944-9.
2
Ocriplasmin use for vitreomacular traction and macular hole: A meta-analysis and comprehensive review on predictive factors for vitreous release and potential complications.
Graefes Arch Clin Exp Ophthalmol. 2016 Jul;254(7):1247-56. doi: 10.1007/s00417-016-3363-5. Epub 2016 Apr 30.
3
Ocriplasmin: who is the best candidate?
Clin Ophthalmol. 2016 Mar 17;10:485-95. doi: 10.2147/OPTH.S97947. eCollection 2016.
4
Real-life experience after intravitreal ocriplasmin for vitreomacular traction and macular hole: a spectral-domain optical coherence tomography prospective study.
Graefes Arch Clin Exp Ophthalmol. 2016 Feb;254(2):223-33. doi: 10.1007/s00417-015-3031-1. Epub 2015 May 5.
本文引用的文献
1
Retinal breaks due to intravitreal ocriplasmin.
Clin Ophthalmol. 2014 Aug 25;8:1591-4. doi: 10.2147/OPTH.S68037. eCollection 2014.
2
Three-dimensional spectral domain optical coherence tomography in vitreomacular traction.
BMJ Case Rep. 2014 Jun 17;2014:bcr2013202065. doi: 10.1136/bcr-2013-202065.
3
Enzymatic vitreolysis with ocriplasmin for vitreomacular traction and macular holes.
N Engl J Med. 2012 Aug 16;367(7):606-15. doi: 10.1056/NEJMoa1110823.
4
A placebo-controlled trial of microplasmin intravitreous injection to facilitate posterior vitreous detachment before vitrectomy.
Ophthalmology. 2010 Apr;117(4):791-7. doi: 10.1016/j.ophtha.2009.11.005.
5
Microplasmin intravitreal administration in patients with vitreomacular traction scheduled for vitrectomy: the MIVI I trial.
Ophthalmology. 2009 Jul;116(7):1349-55, 1355.e1-2. doi: 10.1016/j.ophtha.2009.03.051. Epub 2009 May 17.
6
Posterior vitreous detachment induced by microplasmin.
Invest Ophthalmol Vis Sci. 2004 Feb;45(2):641-7. doi: 10.1167/iovs.03-0930.
7
Tomographic features of a lamellar macular hole formation and a lamellar hole that progressed to a full-thickness macular hole.
Am J Ophthalmol. 2000 Nov;130(5):677-9. doi: 10.1016/s0002-9394(00)00626-7.
8
Effect of plasminogen activator (urokinase), plasmin, and thrombin on glycoprotein and collagenous components of basement membrane.
Cancer Res. 1981 Nov;41(11 Pt 1):4629-36.
9
Age-related changes in human vitreous structure.
Graefes Arch Clin Exp Ophthalmol. 1987;225(2):89-93. doi: 10.1007/BF02160337.
10
Surgical excision of the attached posterior hyaloid.
Arch Ophthalmol. 1988 Jul;106(7):998-1000. doi: 10.1001/archopht.1988.01060140144042.
Zotero 插件